Background: Ardisia crispa Thunb A.DC (Myrsinaceae), commonly known as "hen's eyes", has been traditionally used in treating various inflammatory diseases. The present study evaluated anti-arthritic, gastroprotective and antioxidant activities of Ardisia crispa root hexane extract (ACRH) in various animal models. Methods: Anti-arthritic activity was evaluated in complete Freund adjuvant (CFA)-induced adjuvant arthritis and gastroprotective effect was studied in the ethanol-induced ulcer model in rats. ACRH was further isolated to yield quinone-rich fraction (QRF) and both were analyzed for their total phenolic content, total flavonoid content and antioxidant activities in various antioxidant assays. Both ACRH and QRF were also analyzed for the quinone composition via gas chromatography analysis. Results: ACRH exerted significant reduction of IL-1β and TNF-α at a lower dose range in CFA-induced arthritis, as well as exhibited its cytoprotective effect against ethanol-induced ulcer lesion via involvement of mucosal nonprotein sulfhydryl (NP-SH) groups. ACRH also showed higher phenolic and flavonoid contents, as well as better antioxidant activities than QRF. Conclusions: These findings demonstrated the plant as a potential anti-inflammatory agent, with ACRH succeeded in inhibiting both arthritic and ulcerogenic effect, possibly mediated via its antioxidant effect.
Introduction
Ardisia crispa (Thunb.) A. DC. belonging to Myrsinaceae family is commonly known as "mata ayam" or "mata itik" among Malaysians, and popularly known as "Bai Liang Jin" in China [1] . The root and leaves part of the plant have been claimed to have various medicinal properties based on the ethnomedical information and indigenous uses [2] . In other Asian countries, the plants roots are used in post-natal syndromes and it is also mixed with other plant to treat menstrual pain [3] . While its boiled concoction is applied at the affected sites for throat and chest pain as well as for rheumatism. Skin liniment is made by mixing the leaves and the root together [4] . In addition, the root juice is drunk for healing earache, cough, fever and diarrhea. In China, the root is formulated as an herbal decoction for treating sprain and broken bones [5] . Previous chemical and biological investigation on this plant indicated the presence of triterpenoid saponins, which gave uterocontraction in mice [5] , n-peptide from the whole plant which showed antihypertensive and antiplatelet aggregating properties in vitro [6] , and a benzoquinone compound which exhibited anti-metastatic effect [7] . In the previous study, we have reported the anti-inflammatory, anti-hyperalgesic [8] , anti-pyretic [9] , chemopreventive [10] [11] [12] , antiangiogenic [13, 14] and anti-ulcer effects [15] on ACRH. However, there are still many in vivo studies that have not been investigated in relation to its ethopharmacological claims. Thus far, there was no activity observed on other fractions, i.e. dichloromethane and methanol of its crude ethanol extract (unpublished data). Therefore, the present works describe gastroprotective and anti-arthritic activities of the ACRH. In addition, its antioxidant activities were also assessed to possibly associate the anti-inflammatory effects with its capability in alleviating free radicals.
Materials and methods

Plant material
The plant's root were obtained from Machang, Kelantan, Malaysia, in April 2010 and deposited at the Herbarium of Universiti Kebangsaan Malaysia with a voucher specimen number of 20841.
Preparation of plant extract
The extraction of the root of Ardisia crispa was previously described by Roslida and Kim [8] .
Isolation of quinone-rich fraction (QRF)
The isolation of QRF was previously described by Yeong et al. [16] .
Quinone composition analysis
In order to determine the presence of quinone in the tested samples, i.e. ACRH and QRF, both samples were run via gas chromatography (GC) (Agilent model 5973 MSD) with HP-5 MS column (30 m × 0.25 mm × 0.25 µm) and helium (1 mL/min) as the carrier gas. Temperature of the oven was set from 70°C and gradually increased to 300°C in 6 min later held for 29 min. Approximately 1 µL of sample was injected in splitless mode at an injector temperature of 250°C. Confirmation of the compound of interest, i.e. quinone was compared with the available data [17] .
Experimental animals
Healthy Sprague Dawley rats of either sex (170-250 g bodyweight) procured from Animal Unit of Faculty of Medicine & Health Sciences, Universiti Putra Malaysia were used in this study. Rats were housed in the standard cages at room temperature (25±3 ºC) in 12 hours dark and 12 hours light cycles. Rats were provided standard pellet diet and water ad libitum and were allowed to acclimatize for at least 7 days in the Animal House and 24 hours prior to experiment, rats were only given water ad libitum. All experimental protocols were permitted by the Animal Ethics Committee of Universiti Putra Malaysia with an ethical approval number: UPM/FPSK/-PADS/BR.UUH/00264. All experiments were consistently conducted between 9 am and 5.00 pm.
Experimental design
For phenolic content and antioxidant activities, both samples (ACRH and QRF) were prepared at a concentration of 1 mg/mL in 95 % denatured ethanol. Synthetic antioxidant (BHT), prepared at the same concentration, was used as standard for comparison purpose. For animal studies, 1 % Tween 80 was used for the preparation of all the standard drugs and ACRH doses. It was used as vehicle at the dose of 10 mL/kg for the negative control groups. The doses (3, 10, 30 and 100 mg/kg bwt) and (10, 30, 100 and 300 mg/kg bodyweight) of ACRH were selected for anti-arthritic and gastroprotective studies, respectively, based on the previously reported results. The vehicle and ACRH were administered per oral (p.o.) 1 hour after induction via absolute ethanol. And 24 hours after CFA induction in anti-arthritic study. Indomethacin and carbenoxolone (CBX) were used as the standard drugs at the dose of 10 mg/kg and 100 mg/kg p.o. for anti-arthritic and gastroprotective studies, respectively. Pretreatment with N-ethylmaleimide (NEM) at 10 mg/kg subcutaneously (sc) and L-NAME at 70 mg/kg intraperitoneally (i.p.) or saline were performed 30 min before administration of vehicle, ACRH or standard drug. p.o.); Group III (ACRH 3 mg/kg p.o.); Group IV (ACRH 10 mg/kg p.o.); Group V (ACRH 30 mg/kg p.o.); Group VI (ACRH 100 mg/kg p.o.). On day 0, approximately 100 µL of Complete Freund's adjuvant (CFA) was subcutaneously injected onto the rats' right foot paw to induce adjuvant arthritis (AA) [18] . The next day, all rats were given the aforementioned treatment until day 15. Paw volume was assessed every alternate day via plethysmometer (Ugo Basile, Italy) during the treatment period.
Local tissue collection and enzyme-linked immunosorbent assay (ELISA)
The experiment was terminated on day 15-post injection by fasting the rats overnight and deeply anaesthetized using ether. Afterward, the ankle tissue was cut off and froze at -80°C for further use. Rats were then sacrificed after the tissue collection. When the ankle tissue was ready to use, it was immediately weighed and placed in 0.50 mL of ice-cold homogenization buffer (50 mmol/L NaCl, 10 mmol/L Tris, 2.5 mmol/L MgCl 2 , pH 7.4). The complete protease inhibitor tablet (Boehringer Mannheim, Germany) was instantly added to the buffer and the volume was raised to 50 mL. Ultra-sonic tissue homogenizer was used to homogenize the tissues and later, they were spun at 20,000×g for 30 min at 4°C. The supernatant was then collected and stored at -80°C.
Interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) level of the local tissue homogenate supernatant was determined using ELISA kits (Pierce Biotechnology Inc., USA) according to the procedures recommended by the manufacturer. Optical density was calculated with an automated microplate reader at 450 nm. The IL-1β protein was quantified by comparing the sample to the standard curve generated from the kit. The same procedure was applied to TNF-α assay with the substitution of antibodies specific to that cytokine.
Ethanol-induced gastric mucosal lesion in L-NAME and NEM-pretreated rats
Gastroprotective experiment was conducted by using the procedures described by Arrieta et al. [19] and Matsuda et al. [20] with some modifications, respectively. Prior to the experiment, rats were randomly grouped in six cages, (n=6) and were fasted for 24 h with water ad libitum. Half an hour prior to treatment in all groups, i.e. vehicle control group (1 % Tween 80, 10 mL/kg); positive control group (CBX 100 mg/kg p.o.) and treatment groups (ACRH 10.30, 100 and 300 mg/kg, p.o.), respectively, rats were either pretreated with 70 mg/kg (i.p.) of L-NAME (an inhibitor of nitric oxide synthase) or saline (i.p.) or 10 mg/kg (sc) NEM/ saline (sc). One hour later, all groups were orally induced with 1 mL of absolute ethanol for gastric ulcer. Animals were sacrificed via cervical dislocation an hour after ethanol administration. The stomachs were excised and gastric damage was determined as described previously.
Histological study
Histological changes of stomach scoring were evaluated according to the procedure of Al-Bekairi et al. [21] , in which four categories were separated based on the characteristic of stomach cell tissues as follows: All this changes categories were measured by using grading on scale as follows:
1=normal; 2=title effect; 3=appreciable effect; 4=severe effect; 5=intensively severe effect).
Total phenolic (TPC) and total flavonoid (TFC) contents
Total phenolic and total flavonoid contents were determined by using the procedures described by Ikram et al. [22] and Quettier-Deleu et al. [23] respectively. All tests were made in triplicates. TPC and TFC were expressed as gallic acid equivalent (GAE) and rutin equivalents (RE) mg/g plant extract, respectively [22, 23] .
Antioxidant assays β-Carotene bleaching assay
This assay was conducted according to the method by Ikram et al. [22] . Antioxidant activity (AA) was calculated as percent of inhibition relative to control using the formula:
where DR control and DR sample are degradation bleaching rates of β-carotene of control and sample or BHT, respectively [24] .
2, 2-Diphenyl-1-picryhydrazyl (DPPH) radical scavenging activity
This assay was also conducted according to the previous method [22] . Triplicate measurements were carried out and their activity was calculated based on the percentage of scavenged DPPH
• : Scavenging activity (%)=[1 -(Absorbance of sample at 517 nm/Absorbance of control at 517 nm)] × 100 [22] 
ABTS
•± radical cation scavenging activity
Description of the procedures used was according to the following methods [25] . Ethanolic solutions of known trolox concentrations (1-4 mM) were used for calibration and the results were expressed as µmol trolox equivalent antioxidant capacity (TEAC)/g extract [25] . All tests were made in triplicates.
Ferric reducing antioxidant power (FRAP)
The antioxidant potential of sample was determined based on a calibration curve plotted using ferrous sulfate (FeSO 4 .7H 2 O) at a concentration ranging between 100 µM and 400 µM. The results were expressed as µmol Fe(II)/g extract. All tests were made in triplicates [26] .
Statistical analysis
For in vitro antioxidant activity analyses, data were expressed as mean±standard error of mean (SEM) of triplicate measurements. Statistical comparisons were made using one-way analysis of variance (ANOVA) followed by least significant difference post hoc test for multiple comparisons of mean between groups. Values with p<0.05 were considered statistically significant. Pearson correlation coefficient was also determined. All in vivo data values were expressed as mean±SEM of changes of percentage from control value. Analysis of data was performed using ANOVA followed by Dunnett's multiple comparison tests. The statistical significant value level was set at p<0.05.
Results
Anti-arthritic activity of ACRH Figure 1 shows the measurement of paw volume after the administration of CFA. The CFA-injected paw remained swollen for more than 15 days. The curves of edema plotted against time could be divided into two phases [27] . ACRH at 10 and 30 mg/kg significantly attenuated edema formation (p<0.05), throughout the study. In addition, there is no significant difference of the animal body weight when compared between treated and control groups (unpublished data). Data presented as mean ±S.E.M (n=6 animals). * p<0.05, ** p< 0.01, *** p<0.001 is statistically significant compared to control using one way ANOVA followed by Dunnett's Test.
ACRH effects on local arthritic tissue cytokines
A significant increase in the concentration of pro-inflammatory cytokines, IL-1β and TNF-α was occurred in the local tissues of arthritic animals on the day 15 of CFA injection ( Table 1 ). The effect of ACRH at all doses exerted significant inhibition (p<0.05) of IL-1β level except at 100 mg/kg. Both 10 and 30 mg/kg of ACRH had shown higher efficacy on IL-1β suppression compared to indomethacin. From Table 1 , it was interestingly observed that ACRH suppressed the IL-1β level not in a dose-dependent manner, as the highest dose of 100 mg/kg showed no significant effect. The result is in accordance with Hamsin et al. [13, 14] who reported the therapeutic dose for ACRH in suppressing inflammation-induced angiogenesis and tumor promotion are within that particular dose range. On day 15 post-CFA injection, ACRH at the dose range of 3-30 mg/kg significantly attenuated TNF-α in local arthritic tissue.
Gastroprotective activity of ACRH
In gastroprotective study, at all doses, i.e. 10-300 mg/kg, ACRH exhibited its cytoprotective effect and showed better efficacy when compared to CBX. The cytoprotective effect of ACRH was altered when pretreated with L-NAME as compared to the saline pretreated group. Interestingly, in comparison to saline pretreated group the gastroprotective of ACRH at 30, 100 and 300 mg/kg showed no significant response against ulcer lesion, respectively ( Figure 2) . Thus, this showed that pretreatment of L-NAME did not alter ACRH-induced cytoprotection at all dosage, thereby excluding the role of nitric oxide (NO) in ACRH-mediating cytoprotective effect. On the contrary, CBX exhibited significant inhibition against gastric ulceration in both saline pretreated group and L-NAME pretreated group (Figure 2 ). Various doses of ACRH and carbenoxolone 100 mg/kg administered orally. Data presented as mean ±S.E.M (n=6). * p<0.001 is statistically significant when compared with either pre-treated saline or L-NAME pretreated group using one way ANOVA followed by Dunnett's Test. Data presented as mean±SEM (n=6). *p<0.001 is statistically significant when compared with either pretreated saline or L-NAME pretreated group using one-way ANOVA followed by Dunnett's test.
Animals pretreated with NEM were found to develop more lesion severity when compared to saline pretreated group. For saline pretreated animals that received ACRH at 30 and 100 mg/kg, they produced a reduction in gastric lesion by 95.6 % and 99.3 %, as compared to NEM pretreated group by 57.1 % and 52.6 % respectively. Moreover, at 300 mg/kg, ACRH significantly suppressed the gastric lesion (p<0.05) by 99.1 % in saline pretreated animals when compared to NEM group (70.0 %) (Figure 3) . Thus, the significant attenuation (p<0.05) at dose range 30-300 mg/kg showed that there is strong participation of sulfhydryl (SH) in gastroprotective effect of ACRH. Various doses of ACRH and carbenoxolone 100 mg/kg administered orally. Data presented as mean ±S.E.M (n=6). * p<0.001 is statistically significant when compared with either pre-treated saline or NEM pretreated group using one way ANOVA followed by Dunnett's Test. Data presented as mean ±SEM (n=6). *p<0.001 is statistically significant when compared with either pretreated saline or NEM pretreated group using one-way ANOVA followed by Dunnett's test.
Histological evaluation
From histological observation, a blockage of NO in the vehicle control group was observed in L-NAME pretreated animals, which led to significant reductions (p<0.01) in the mean score of blood congestion and significant increase (p<0.001) in necrosis feature scoring (Table 2) . On the other hand, in L-NAME pretreated animals, 100 mg/kg CBX was found to cause significant blood congestion and hemorrhage features (p<0.05) which confirmed the possible involvement of NO in its cytoprotective mechanism. Interestingly, at 300 mg/kg; ACRH significantly increased the appearance of all histological features which include blood congestion, hemorrhage and necrosis. Thus, from the data obtained, only the highest dose of ACRH (300 mg/kg) may be able to cause cytoprotective activity with the presence of NO. There was insignificant change on severity of edema and blood congestion between both control groups of pretreated saline and pretreated NEM when observed under microscope. In contrast, pretreated NEM on ACRH at all dose exhibited significant changes in hemorrhage respectively. The current data which significantly attenuated the ulcerogenic inhibition thus signified a possible participation of SH in ACRH gastroprotection against ulcerogenic activity (Table 2) .
Quinone composition analysis of ACRH and QRF
ACRH and QRF were subjected to quinone (phenolic) content analysis by GC, prior to determination of their phenolic contents and antioxidant activities. GC analysis ( Figure 4A and 4B) showed similar retention time of quinone compound found in ACRH (18.886 minutes) and QRF (18.905) with that of standard quinone (18.897 min) (data not shown). Percentage of yield, TPC and TFC of ACRH and QRF are depicted in Table 3 . Though statistical analysis showed no significant difference between ACRH and QRF in their phenolic and flavonoid contents, results indicated that ACRH contained greater amount of both compounds, reporting 103.51 mg GAE/g extract and 31.83 mg RE/g extract, respectively. Table 3 summarizes findings from antioxidant activities of ACRH and QRF. β-carotene bleaching assay showed that BHT had greater antioxidant activity which was significantly different from QRF. All samples were found to be significantly different (p<0.05) in DPPH assay. BHT showed higher percentage of free radical scavenging activity followed by ACRH and QRF. In ABTS assay, QRF showed higher antioxidant capacity than ACRH but were still lower than BHT. In FRAP and DPPH assays, all samples were found to be significantly different (p<0.05) with the rank of BHT>ACRH>QRF. Correlations between TPC, TFC and antioxidant assays were analyzed and presented in Table 4 . 
Antioxidant activities of ACRH and QRF
Discussion
Herbal medicines have been efficaciously studied in various acute and chronic inflammatory cases, including arthritic illnesses [28] . The present study evaluated the in vivo anti-arthritic and gastroprotective activities of the hexane fraction of the root of Ardisia crispa (ACRH), as well as its antioxidant effects. ACRH was chosen in this study as previous studies have reported several prophylactic and therapeutic effects manifested by ACRH in various in vivo inflammatory studies. In this study, oral administration of ACRH at lower dose range of 3-30 mg/kg caused a significant paw edema suppression by significantly lowered the concentration of the pro-inflammatory cytokines TNF-α and IL-1β, produced by the activated macrophages and T-cells at the local inflammation site in the AA which play crucial roles in the pathogenesis of rheumatoid arthritis (RA). Redlich et al. [29] had proven the efficacy of both aforementioned pro-inflammatory cytokines in their inhibition studies.
We also investigated the possible anti-arthritic mechanism of ACRH by evaluating the inhibition of TNF-α and IL-1β secretion in adjuvant-induced arthritis (AIA) rat local tissues which were significantly elevated in the untreated AIA rats, in our current study. Zhang and An [30] had demonstrated the significant elevation of TNF-α, IL-1β as well as nerve growth factor in the inflamed paw when injected with CFA on the intraplantar of adult rats. TNF-α has been shown to play a key role in the development of RA by mediating an array of immune effector functions including the induction of the inflammatory response and pannus formation. It has also shown to support the cartilage destruction and bone erosion of RA [31] .
In addition, other pro-inflammatory cytokines, such as IL-1β, IL-6 and complement components, are also released from immune cells in both AA and RA [32] . Specifically, during cell injury, infection, invasion and inflammation, apart from monocytes and macrophages, non-immune cells, such as fibroblasts and endothelial cells tend to release IL-1β [30] . These cytokines caused cartilage and bone destruction by activating both neutrophils and macrophages at an infectious joint. During a period of infection or inflammation, defense cells took part in immune mechanism, which leads to NF-κβ to be activated and more IL-1β and TNF-α are released to cause pathogenesis [33] . According to Szekanecz and Koch [34] , vascular endothelial growth factor (VEGF) acts as a mediator in patients with moderate arthritis. This mediator is released from synovial tissue or fibroblasts and fluids via secretion of IL-1β and TNF-α [35] . By inhibiting these two cytokines, it will effectively reduce acute and chronic inflammatory features of diseases such as edema, cartilage damage and synovial proliferation [36] . In another in vitro study, ACRH has been shown to suppress VEGF as part of its antiangiogenic mechanism (unpublished data). RA is one of the diseases due to the excessive angiogenesis and it is said that by suppressing angiogenesis, in general and VEGF, in particular the RA development will also be reversal.
Some immunohistochemistry studies have strongly proven that IL-1β, IL-6, TNF-α, prostaglandin, VEGF and fibroblast growth factors were highly elevated in local tissue in AIA [36] . Based on the present results, ACRH at 10 and 30 mg/kg as well as indomethacin, significantly suppressed the edema formation throughout the experimental period. It also inhibited IL-1β and TNF-α level after 14-days CFA post-injection, thus suggested that ACRH might regulate its anti-arthritic effect by suppressing NF-κβ pathway, which in turn blocks the releasing of TNF-α and IL-1β from synovial cells or fibroblast-like synoviocytes. It has been documented that the anti-inflammatory effect of indomethacin mediated via cyclooxygenase (COX), IL-1β and TNF-α through the activation of NF-κβ, a transcription factor for cytokines and chemokines' genes encoding [37] , which also in accordance with Hamsin et al. [13] . Yeong et al. [38] have reported the antitumor promotion of QRF mediated via NF-κβ, thus suggesting similar pathway might be attributed to its effect against chronic inflammation, i.e. RA. Nevertheless, further studies should be done in proving the hypothesis.
Ethanol-induced gastric injury in animal model provides a mean for assessing agents with potential antiulcer actions as well as their implicated mechanisms for gastric protection as this model able to mimic several features of the human condition [39] . Previous study reported that ACRH reduced the ethanol-induced ulcer lesion in rat [15] . Therefore, in this current study, we tried to determine the possible mediators involved in its gastroprotective effect by testing it on either L-NAME (a nitric oxide (NO) synthase inhibitor) or NEM (a sulfhydryl (SH) inhibitor) pretreated animals, respectively. NO and SH were reported to play an important role as main mediators in aggressive inflammation. In gastrointestinal disorder, many factors are reported to contribute ulcer lesion such as non-steroidal anti-inflammatory drugs (NSAIDs), hydrochloric acid, bicarbonate, prostaglandins (PGs), cell regenerations, hormone, stress, lack of mucus as well as inhibition of NO and SH groups [40] .
Oxidative stress and lipid peroxidation can be induced by acute ethanol challenge, followed by the destroying of the mucosal barrier, thus led gastric wall mucus depletion [41] . Pro-inflammatory cytokines, oxidative stress and apoptosis have been evidenced to play major roles in the pathogenesis of ethanol-induced ulceration [42] . Oxidative stress could cause cell damage and in order to minimize the damages, antioxidants could help to protect the cells by enhancing the body's defense systems against oxidative stress as well as in degenerative diseases. In addition, their defence role against oxidative stress caused by necrotic agents is an important factor in defending the gastric mucosa [43] .
Undeniably, the mucous synthesis that strengthens the mucosa barrier against harmful agents also has an important role in gastro protection endogenous non-protein-sulfhydryl (NP-SH) compounds has been shown to become one of the key agents in mucosal protection against ethanol-induced gastric injury where the development of damage was accompanied by a lowering in production of mucosal SH compounds [44] . In addition, NO has also shown to be involved in the enhancement of mucosa cytoprotection mechanisms, manifested by its effect in promoting blood vessel dilatation and reducing lipoperoxidation while acting similarly to an antiinflammatory drug [45] .
In the current study, there was no significant increase in the gastric ulcer after blocking of NO production with L-NAME, thus suggesting that ACRH gastroprotective effect is not mediated via NO pathway. On the contrary, there might be an involvement of NO in CBX's cytoprotective pathway. However, it can be confirmed by either evaluating or examining the presence of inflammatory features in the histological study. On the contrary, there was a decrease in gastric ulcer area after pretreatment with NEM in ACRH-treated animals which indicated a significant improvement in the depleted level of NP-SH, thus evidencing a strong participation of the endogenous NP-SH in the gastroprotective effect of ACRH.
Apart from its involvement in controlling the nature and mucus production as well as in recycling antioxidant, NP-SH compounds also bind the free radicals formed following tissue injury by noxious agents including ethanol [46] which also associate NP-SH with oxidative stress. Therefore, the antioxidative compounds present in ACRH can prevent the loss of gastric mucus and NP-SH, since they are able to remove free radicals formed by the ethanol-induced mucosal ulcer [46] .
The findings have been supported by the current microscopic data which thus confirmed a strong involvement of SH pathway in gastroprotection of ACRH (Table 2) . CBX, on the other hand, did not exhibit any significant difference between saline and NEM pretreated group, confirming there is no involvement of SH in CBX's cytoprotective effect.
Overall, present gastroprotective study suggested that ACRH can be used to promote ulcer healing via -SH involvement. ACRH has been shown to possess antioxidant activity which may also contribute to the strong involvement of endogenous SH in the gastroprotection of ACRH, indicated by the significant attenuation of gastric lesions.
Free radicals are largely released into the surrounding tissues of RA patients, eventually leads to tissue damage [47] . While, in ethanol-induced ulceration, oxidative stress and free radical formation play major roles in disrupting the mucus-bicarbonate barrier in the gastric mucosa and damaging the wall of blood vessels [43] . Thus, inhibition of the deleterious effects of free radicals in AIA and ethanol-induced ulcer could be attributed to its antioxidant property. Previously, antioxidative agents have displayed favorable actions in protecting gastric ulcer induced by alcohol Phenolic compounds exert their roles via neutralizing free radicals, quenching singlet and triplet oxygen, and breaking down peroxides [48] . Our current findings indicated that flavonoids present in ACRH and QRF do not contribute largely to the phenolic content and antioxidant activities, but the presence of other phenolic compounds, either non-soluble compounds (condensed tannins, lignins, cell-wall bound hydroxycinammic acids) or soluble compounds (phenolic acid, phenylpropanoids, quinones) is highly suggestive [49] .
Despite that, antioxidant activities of ACRH and QRF were in accordance with their phenolic amounts. ACRH, which contained higher amount of phenolics, showed better antioxidant activities than QRF where BHT>ACRH>QRF was observed in almost all antioxidant assays. According to André et al. [50] , phenolic compounds can exert synergistic and antagonistic effects with other phenolic or non-phenolic components. There-fore, greater percentage of non-phenolic compounds in QRF could have led to more prominent antagonistic interaction with phenolic compounds, rather than synergistic effect. This finding is in agreement with previous report on QRF, which exhibited less activities compared to ACRH [16, 38] .
Results obtained in this study indicated that ACRH contained higher phenolic content and greater antioxidant activities than QRF, without considerable contribution from flavonoid compounds. It is noteworthy that despite the availability of various evaluation methods for determination of antioxidant activities, comparison of results obtained in one study to another is rather difficult due to variations in method of sample preparation, solvent and analytical condition. Nevertheless, findings from current research laid an essential foundation for further study of other phytochemicals and antioxidants of Ardisia crispa. It is recommended that antioxidant activities of other phytochemicals such as terpenes, quinone or tannin be determined in the future to provide more comprehensive information on antioxidant activities of Ardisia crispa.
Conclusions
The results of the present study manifested the anti-arthritic effect of ACRH mediated via significant proinflammatory cytokines suppression, i.e. TNF-α and IL-1β. ACRH also exhibits gastroprotective activity against ethanol-induced gastric lesions via -SH involvement. This suggests that, ACRH may be beneficial as an adjuvant to conventional drugs in the treatment of arthritis and related inflammatory disorders such as gastric ulcer. As ACRH has shown better antioxidant activities due to its phenolic compound, in which we believed is due to the quinone composition and other favorable non-flavonoid compounds, both anti-arthritic and gastroprotective of ACRH might be partially attributed to its antioxidant properties.
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